Maryo Antoine Baakliny

Mr. Maryo Antoine Baakliny

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Linda Abou-AbbasLinda Abou-Abbas
Linda Abou-Abbas
ZNZeina Nasser
Zeina Nasser
MBMaryo Antoine Baakliny
Maryo Antoine Baakliny
LCLina Chaito
Lina Chaito
JKJeanette Karout
Jeanette Karout
HHHamad Hassan
Hamad Hassan
Since the beginning of the COVID-19 pandemic, the Epidemiological surveillance program of the Lebanese Ministry of Public Health has launched a rapid surveillance system for collecting COVID-19-related mortality data. In this study, we document the Lebanese experience of COVID-19 mortality surveillance and provide an analysis of the epidemiological characteristics of confirmed deaths. The implementation of the rapid COVID-19 mortality surveillance system, data sources, and data collection were described. A retrospective descriptive analysis of the epidemiological characteristics of confirmed cases occurring in Lebanon between February 20, 2020, and September 15, 2021, was performed. Epidemiological curves of Covid-19 confirmed cases and deaths as well as the geographic distribution map of mortality rates were generated. Between February 21, 2020, and September 15, 2021, a total of 8163 COVID-19-related deaths were reported with a predominance of males (60.4%). More than 60% were aged 70 years or above. Of all deaths, 84% occurred at hospitals and 16% at home. The overall cumulative mortality rate was 119.6 per 100,000. The overall case fatality ratio (CRF) was 1.3%. Of the total deaths, 82.2% had at least one underlying medical condition. The top reported COVID-19 comorbidities associated with COVID-19-related deaths are cardiovascular diseases including hypertension (59.1%), diabetes (37.2%), kidney diseases including dialysis (11%), cancer (6.7%), and lung diseases (6.3%). The CFR was 30.9% for kidney diseases, 20.2% for cancer, 20.2% for lung diseases, 18.1% for liver diseases, 14% for diabetes, and 12.2% for cardiovascular diseases. Considering the limited human and financial resources in Lebanon due to the economic and political crisis, the rapid mortality surveillance system can be considered successful. Improving this system is important and would contribute to better detection of deaths from emerging and re-emerging diseases during health crises.

18 July 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
FAFirass Abiad
Firass Abiad
AAAbdinasir Abubakar
Abdinasir Abubakar
NHNadeen Hilal
Nadeen Hilal
WGWahida Ghalayini
Wahida Ghalayini
NGNada Ghosn
Nada Ghosn
ACAbrar Ahmad Chughtai
Abrar Ahmad Chughtai
On 6 October 2022, the first cholera outbreak in three decades was reported in Lebanon by the Ministry of Public Health (MoPH). The outbreak spread across all 8 governorates (23 out of 26 districts). From October 2022 to June 2023, a total of 8,072 cases (including 671 lab-confirmed cases) and 23 deaths were reported, resulting in a case-fatality ratio of 0.28 percent. The outbreak was successfully contained through the implementation of coordinated, multisectoral prevention and control strategies, supported by both national and international stakeholders. The cholera vaccine campaign with one-dose strategy was started in November 2022. The proportion of vaccinated people among the target population evolved from 4.8% in November 2022, to 30.6% in December 2022, 34.2% in January 2023 and 45.3% in February 2023. This paper describes the epidemiology of cholera outbreak in Lebanon and summarises outbreak response in the context of a humanitarian emergency.

Abass JounyAbass Jouny
Abass Jouny
HSHawraa Sweidan
Hawraa Sweidan
MBMaryo Antoine Baakliny
Maryo Antoine Baakliny
NGNada Ghosn
Nada Ghosn
During the 2022–2023 cholera outbreak in Lebanon, cases were reported through the District Health Information System 2 (DHIS2). We developed automated procedures in R computing language to improve completeness of routinely notified variables, apply case definition criteria, improve geographic accuracy and documentation of laboratory results. We developed R scripts for data cleaning, standardization, and reclassification, plotted epidemic curves and produced maps to display cholera incidence rates and rapid diagnostic test (RDT) coverage by district. We shared the R scripts on GitHub platform for open adaptation and use. Prior to cleaning, missingness reached 99.7% for inpatient status and 17–35% for other key variables. After cleaning, all fields were complete. Initially, 92.8% of cases were notified through DHIS2 as suspected and 7.2% as confirmed. Following reclassification, 40% were classified as suspected, 5.8% as confirmed, and 48.6% with unspecified classification. Laboratory data revealed that 5.8% of cases were culture positive, 2.2% RDT positive, and 65.1% had no documented testing. Among facility-entered cases (n = 5953), 11.4% were reported from a different governorate than the patient’s residence. At the time of the outbreak, the daily maps were generated based on place of residence. Integrating R-based analytics with DHIS2 enhanced data completeness, improved case classification, and enabled more better spatial and laboratory analysis. This combined approach provided a clearer epidemiological picture of the cholera outbreak, supporting data-driven public health decision-making and highlighting the value of integrating analytical tools with routine surveillance systems.

30 June 2026 in BMJ Open
Verified
Journal Article
Open access
MBMaryo Antoine Baakliny
Maryo Antoine Baakliny
NGNada Ghosn
Nada Ghosn
NSNadine Saleh
Nadine Saleh
PMPatrick Maison
Patrick Maison
Objectives: To evaluate knowledge, attitudes and practices towards routine vaccination in the Lebanese population in the post-COVID-19 period, and to examine differences between COVID-19 vaccinated and non-vaccinated individuals. The study also aimed to identify sociodemographic and behavioural factors associated with vaccination status, and to explore changes in vaccination practices before and after the pandemic. Design: Unmatched case-control study. Setting: Community-based survey conducted across all regions of Lebanon between July and October 2023. Participants: A total of 730 adults were included, comprising 277 COVID-19-positive individuals who were not vaccinated against COVID-19 (cases) and 453 COVID-19-positive individuals who had received at least one dose of a COVID-19 vaccine (controls). Participants were randomly selected from the national COVID-19 surveillance database. Adults aged ≥18 years were eligible; individuals who tested negative for COVID-19 or were unable to provide consent were excluded. Primary and secondary outcome measures: Primary outcomes were vaccination knowledge and attitudes, measured using the Zingg knowledge scale and the 7C vaccination attitude scale. Secondary outcomes included self-reported adherence to routine and influenza vaccination before and after COVID-19. Factors associated with non-vaccination were examined using multivariable regression models. Results: Vaccinated participants were older and more likely to be employed, have higher education, work in healthcare and report financial coverage for vaccines. They had higher knowledge scores, more positive attitudes towards vaccination and increased adherence to routine and influenza vaccination after COVID-19, while adherence declined among non-vaccinated participants. In multivariable analysis, older age (OR 0.98, 95% CI 0.96 to 0.99), higher education (OR 0.68, 95% CI 0.60 to 0.78), number of children (OR 0.88, 95% CI 0.78 to 1.00) and more positive vaccination attitudes (OR 0.97, 95% CI 0.94 to 1.00) were independently associated with lower odds of non-vaccination. Conclusions: Older age, higher education, greater number of children and more positive attitudes were associated with lower odds of non-vaccination. Vaccinated participants also had higher knowledge scores, more positive attitudes and better adherence to routine and influenza vaccination practices than non-vaccinated participants.

20 March 2025 in PLOS ONE
Verified
Journal Article
Open access
MBMaryo Antoine Baakliny
Maryo Antoine Baakliny
NGNada Ghosn
Nada Ghosn
NSNadine Saleh
Nadine Saleh
PMPatrick Maison
Patrick Maison
The emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the subsequent coronavirus disease 2019 (COVID-19) pandemic with the continuous evolution of the virus into variants such as Alpha, Beta, Delta, Omicron and others necessitates an on-going surveillance and evaluation of vaccine effectiveness (VE).This study focuses on assessing the real-world performance of the Pfizer-BioNTech (BNT162b2) vaccine against the Omicron variant. This study employs a test-negative, case-control design, a methodology commonly utilized for estimating the VE in influenza studies. It evaluates SARS-CoV-2 test results in individuals aged 50 and older who had influenza-like illness (ILI) or COVID-like illness (CLI) symptoms and presented to the sentinel sites, classifying positive cases as “cases” and negative as “controls.” Data collection was done through a standardized questionnaire administered by the Epidemiological Surveillance Unit (ESU) COVID-19 team via phone interviews. Logistic regression analysis was performed to measure the association, taking into account all confounding factors. The results indicate a 14% VE against contracting the disease among fully vaccinated individuals. Factors such as age and underlying conditions significantly influenced VE. The findings of this study highlight the effectiveness of the Pfizer-BioNTech (BNT162b2) vaccine in reducing the odds of symptomatic COVID-19, particularly by decreasing the prevalence of key symptoms such as fever, cough, myalgia, and loss of taste or smell. Breakthrough infections still occurred, indicating that while the vaccine reduces symptom severity, it may not fully prevent infection This VE is lower compared to previous variants, indicating potential challenges in vaccine efficacy. The study underscores the need for an on-going monitoring and potential booster doses to enhance protection, especially against evolving variants like Omicron.

1 February 2022 in medRxiv
Verified
Preprint
Open access
PDF file
MBMaryo Antoine Baakliny
Maryo Antoine Baakliny
JNJulia Naim
Julia Naim
AHAya Hage
Aya Hage
TTTatiana Tohmeh
Tatiana Tohmeh
RMReem Abdel Malak
Reem Abdel Malak
NGNada Ghosn
Nada Ghosn
Background On the 11th March, the WHO has declared COVID-19 pandemic. Officially, the virus was introduced in Lebanon on the 21st February 2020. Since then, the national curve has drawn several waves. From July to September 2021, Lebanon has experienced the first delta wave. As part of the investigation, contact tracing was enhanced to limit virus transmission. The objective is to describe close tracing approach and profile of close contacts identified during the first delta wave. Methods COVID-19 surveillance is integrated within the national communicable diseases surveillance. The case definitions are adopted from WHO guides. Laboratories report positive cases on daily basis to the Ministry of Public Health, on DHIS2 platform directly or indirectly via excel files importation. Once reported, case investigation is initiated. It includes contact tracing with: 1) identification of close contacts, 2) advice on quarantine and self-monitoring, 3) contact testing. Referral to field testing is made available free of charge for close contacts. Collected data is updated on DHIS2 platform. Later, data is cleaned and analyzed to generate the daily report including description of close contacts. The report is shared with decision makers, professionals, media and public. Results From week 2021W27 to week 2021W40, 85490 cases were reported. Case investigation rate reached 78.8% of the cases were investigated within 24 hours. 66.5% of investigated cases shared lists of contacts, with 3.6 as average number of contacts per case. We identified a total of 161805 close contacts, 95% were from family members, 71% were not vaccinated and 10 % had prior COVID-19 infection. As for contact testing, 65% had RT-PCR test upon investigation, with 32% positive result. Furthermore, 19205 were referred and tested via field testing, with 25% positivity rate. Of all identified contacts, the reported positive tests reached 56,904 representing 35.2% of all contacts. Conclusion During community transmission and mitigation strategy, contact tracing contributes to increase awareness to the contacts and importance to abide to quarantine measures and thus to slow down the virus circulation. Current close contacts are characterized with new profile of prior infection, vaccination history and testing behavior. There is need to adapt the quarantine measures to close contacts based on their profile, and to ensure easy access to free testing.